An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge.
Herpes simplex virus types 1 and 2 (HSV1 and HSV2) are common infectious agents in both industrialized and developing countries. They cause recurrent asymptomatic and/or symptomatic infections, and life-threatening diseases and death in newborns and immunocompromised patients. Current treatment for...
Main Authors: | Mariaconcetta Sicurella, Francesco Nicoli, Eleonora Gallerani, Ilaria Volpi, Elena Berto, Valentina Finessi, Federica Destro, Roberto Manservigi, Aurelio Cafaro, Barbara Ensoli, Antonella Caputo, Riccardo Gavioli, Peggy C Marconi |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4102458?pdf=render |
Similar Items
-
The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral Reactivation
by: Francesco Nicoli, et al.
Published: (2020-06-01) -
The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses.
by: Francesco Nicoli, et al.
Published: (2013-01-01) -
Mangiferin-Loaded Smart Gels for HSV-1 Treatment
by: Mariaconcetta Sicurella, et al.
Published: (2021-08-01) -
Efficacy of the anti-VZV (anti-HSV3) vaccine in HSV1 and HSV2 recurrent herpes simplex disease: a prospective study
by: Le Goaster J, et al.
Published: (2012-07-01) -
Characterisation of the herpes simplex virus type 1 (HSV-1) triplex proteins
by: Boutell, Christopher John
Published: (2000)